Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Symbio Pharmaceuticals Limited ( (JP:4582) ) just unveiled an update.
SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the fiscal year 2024, with net sales falling by 56.1% and a substantial increase in net loss compared to the previous year. The company continues to face challenges, including a decrease in total assets and cash equivalents, while planning a new subsidiary in the USA, which may impact its future operations and market positioning.
More about Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing oncology and rare disease therapies.
YTD Price Performance: -8.54%
Average Trading Volume: 304,634
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen8.34B
For a thorough assessment of 4582 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue